What You Should Know:
– Phenomix Sciences, a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, announces a new partnership to advance precision medicine in obesity with InformedDNA, the nation’s leading applied genomics solutions company.
– The collaboration integrates Phenomix’s MyPhenomeTM genetic obesity test with InformedDNA’s DNAimpactTM precision health platform, broadening access to genetics-based weight management care for InformedDNA’s extensive network of payers, health systems, employers, and life sciences organizations.
Optimizing Obesity Treatment Through the MyPhenome Saliva Test
The MyPhenome test offers a genetic-based approach to obesity management, enabling providers to uncover the biological underpinnings of obesity and align treatments—including GLP-1 receptor agonists—more precisely to patient needs.
Research highlights that anti-obesity medication responses vary widely among individuals and are unrelated to factors like age, BMI, race, or comorbidities. Tailoring treatments to a patient’s biological traits, as identified by the MyPhenome test, has been shown to be twice as effective as generalized, one-size-fits-all interventions.
With support from InformedDNA’s board-certified genetics experts, patients receive:
– Guidance throughout the saliva test process
– Interpretation of personalized reports explaining the biological causes of their obesity
– Ongoing care and follow-up to enhance treatment outcomes
The test results provide healthcare professionals with actionable insights to develop comprehensive treatment plans, including:
– Lifestyle modifications and dietary adjustments
– Medication regimens tailored to the patient’s genetic profile
– Procedural recommendations when necessary
By shifting focus from traditional metrics to biologically informed care, the MyPhenome test empowers providers to deliver precise, effective weight management solutions.
“We are excited to collaborate with InformedDNA, a trusted genomics company that has been working with health plans on the appropriate use of genetic testing for over a decade,” said Mark Bagnall, CEO of Phenomix Sciences. “By integrating our MyPhenome genetic test with their DNAimpact precision health platform, we’re expanding access to expert decision support for patients and their clinicians throughout the U.S. This partnership represents a critical step forward in addressing the complexities of metabolic syndrome and obesity, improving patient outcomes, and making personalized healthcare more accessible to those who need it most.”
